Nagaoki Toyoda

Publications (52) View all

• Article: [Drug-induced thyroid dysfunction].

  Mitsushige Nishikawa, Nagaoki Toyoda, Emiko Nomura
  [show abstract] [hide abstract]
  ABSTRACT: Various drugs may cause thyroid dysfunction. The drugs which may cause thyrotoxicosis include interferon, molecular-targeted agents, amiodarone, thyroid hormone itself and so on. Those which cause hypothyroidism include anti-thyroid drugs, lithium and iodine etc. which inhibit thyroid hormone synthesis and secretion, and dopamine etc. which block TSH secretion. Those drugs which alter the thyroid hormone metabolism or the binding to TBG or those inhibit thyroid hormone absorption may cause hypothyroidism or deteriorate it in patients with hypothyroidism treated with thyroid hormone or those with diminished reserved capacity. When thyroid dysfunction occurred, it is better to discontinue the causative drug, but in many cases, the patients are forced to be treated with the drug being continued.
  Nippon rinsho. Japanese journal of clinical medicine 11/2012; 70(11):1958-64.
• Article: [Hypothyroidism].

  Mitsushige Nishikawa, Nagaoki Toyoda, Emiko Nomura
  Nippon rinsho. Japanese journal of clinical medicine 08/2012; 70 Suppl 6:725-30.
• Article: [Case report; Plummer disease associated with acromegaly].

  Satoko Higashiyama, Nagaoki Toyoda, Emiko Nomura, Tomoki Fujio, Chizuko Ukita, Mitsushige Nishikawa, Toshiji Iwasaka
  Nihon Naika Gakkai Zasshi 03/2012; 101(3):763-5.
• Article: Olmesartan induces renoprotective effects by stimulating angiotensin type 2 receptors and reducing oxidative stress in diabetic nephropathy.

  Fusakazu Jo, Satoshi Morimoto, Mitsutaka Nakahigashi, Makiko Kusabe, Kazunori Someya, Tatsuyori Morita, Hiromi Jo, Takanobu Imada, Atsushi Kosaki, Nagaoki Toyoda, Mitsushige Nishikawa, Toshiji Iwasaka
  [show abstract] [hide abstract]
  ABSTRACT: Angiotensin receptor blockers reduce the progression of diabetic nephropathy primarily by inhibiting angiotensin type 1 (AT(1)) receptors. In the present study, we investigated the role of angiotensin type 2 (AT(2)) receptors on the renoprotective effects of olmesartan in diabetic nephropathy. Six-week-old mice were treated with streptozotocin and divided into four groups: the OLM group (mice treated with olmesartan), the OLM+Ang II group (mice treated with olmesartan and angiotensin II), the OLM+PD group (mice treated with olmesartan and the AT(2) antagonist PD 123319), and the vehicle group. Nondiabetic mice were used as controls. We measured blood glucose levels and urinary excretions of albumin and 8-hydroxy-2'-deoxyguanosine (8-OHdG), which is a marker for oxidative stress. Although urinary albumin excretion in the OLM and OLM+Ang II groups showed a tendency to be reduced compared to the vehicle group, it was significantly lower compared to the OLM+PD group. Urinary excretion of 8-OHdG was also significantly lower in the OLM and OLM+Ang II groups compared to the OLM+PD group. In diabetic nephropathy, the renoprotective effects of olmesartan are due not only to the blockade of AT(1) receptors, but also to a reduction in oxidative stress via stimulation of AT(2) receptors.
  Kidney and Blood Pressure Research 06/2011; 34(6):418-23. · 1.46 Impact Factor
• Article: [Physiological factors that control thyroid function].

  Mitsushige Nishikawa, Nagaoki Toyoda, Emiko Nomura
  Nippon rinsho. Japanese journal of clinical medicine 03/2011; 69 Suppl 2:81-4.